Cwm, LLC Dynavax Technologies Corp Transaction History

Cwm, LLC

$28.4 Billion
Q2 2025

A detailed history of Cwm, LLC transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Cwm, LLC holds 1,515 shares of DVAX stock, worth $17,210. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,515

Previous 2,546 40.49%

Holding current value

$17,210

Previous $33,000 54.55%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 25, 2025	SELL	$9.4 - $12.87 $9,691 - $13,268	-1,031 Reduced 40.49%	1,515 $15,000
Q1 2025 May 01, 2025	BUY	$12.39 - $14.4 $5,389 - $6,264	435 Added 20.61%	2,546 $33,000
Q4 2024 Feb 04, 2025	BUY	$10.28 - $13.66 $3,197 - $4,248	311 Added 17.28%	2,111 $27,000
Q3 2024 Oct 08, 2024	BUY	$10.05 - $11.61 $5,145 - $5,944	512 Added 39.75%	1,800 $20,000
Q2 2024 Jul 09, 2024	BUY	$10.73 - $12.58 $6,888 - $8,076	642 Added 99.38%	1,288 $14,000
Q1 2024 Apr 05, 2024	BUY	$11.7 - $14.98 $2,152 - $2,756	184 Added 39.83%	646 $8,000
Q4 2023 Feb 01, 2024	SELL	$13.09 - $14.98 $1,793 - $2,052	-137 Reduced 22.87%	462 $6,000
Q3 2023 Oct 11, 2023	BUY	$12.64 - $14.99 $1,074 - $1,274	85 Added 16.54%	599 $9,000
Q2 2023 Aug 03, 2023	BUY	$9.85 - $13.17 $5,033 - $6,729	511 Added 17033.33%	514 $7,000
Q1 2023 Apr 28, 2023	SELL	$9.44 - $11.88 $3,521 - $4,431	-373 Reduced 99.2%	3 $0
Q4 2022 Feb 01, 2023	BUY	$10.27 - $13.29 $328 - $425	32 Added 9.3%	376 $4,000
Q3 2022 Oct 27, 2022	BUY	$9.93 - $17.44 $3,415 - $5,999	344 New	344 $4,000

Others Institutions Holding DVAX

# of Institutions

305

Shares Held

129M

Call Options Held

493K

Put Options Held

269K

View Full List

About DYNAVAX TECHNOLOGIES CORP

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.44B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

More about DVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account